The patients given EMA401 reported significantly less pain compared with baseline values in the final week of treatment than did those given placebo ( mean reductions in pain scores -2.29 [ SD 1.75 ] vs -1.60 [ 1.66 ] ; difference of adjusted least square means -0.69 [ SE 0.25 ] ; 95 % CI -1.19 to -0.20 ; p = 0.0066 ) .